Compare F5 Inc (FFIV) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Novo Nordisk A/S — how do they compare? F5 Inc trades at $480.89 (market cap $26.14B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 6.3× F5 Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while F5 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Novo Nordisk A/S for 116 Days on average.
| FFIV | NVO | |
|---|---|---|
Market Cap | $26.14B | $165.31B |
Volume | 503,146 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $469.79 | $63.98 |
52-Week Low | $223.99 | $35.29 |
Typical Hold Time | 38 Days | 116 Days |
Enterprise Value | $24.78B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $479.83, up 2.82% today and near its 52-week high, reflecting strong momentum. The stock shows bullish technical signals with recent earnings beats and robust revenue growth, reaching $3.09 billion in 2025. Positive sentiment is driven by leadership in AI security and strategic partnerships, though valuation multiples like a P/E of 36.78 suggest premium pricing. Cash flow remains healthy with $268 million net inflow in 2025, supporting operational strength.
Outlook is cautiously optimistic with growth in AI and security markets offering upside, but risks include high valuation and competitive pressures. Analysts are mixed with a $416.60 consensus target below current price, indicating potential overvaluation. Investors should weigh solid fundamentals against elevated multiples for balanced risk-reward.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
